Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration using a variable frequency regimen in eyes with no previous treatment.

@article{Fong2008IntravitrealB,
  title={Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration using a variable frequency regimen in eyes with no previous treatment.},
  author={Kenneth Choong Sian Fong and Nigel Kirkpatrick and Quresh Amir Mohamed and Robert L. Johnston},
  journal={Clinical & experimental ophthalmology},
  year={2008},
  volume={36 8},
  pages={748-55}
}
PURPOSE To evaluate a variable frequency regimen with intravitreal bevacizumab for treatment of neovascular age-related macular degeneration (AMD) in eyes that have not received any previous treatment. METHODS Retrospective review of patients with neovascular AMD who were treated with three consecutive monthly intravitreal injections of bevacizumab (1.25 mg) and retreated based on the PrONTO study criteria. Outcome measures included visual acuity (VA) and central retinal thickness. Subgroup… CONTINUE READING